NMN and NR: what oral supplements have shown

The question “Does NMN work?” needs a second part: for what, in whom and for how long? A laboratory change, better walking in people with vascular disease and prevention of disability over years are different outcomes. The evidence below concerns oral supplements and reflects research through September 22, 2026. [1] [2] [3] [4] [5] [6] [14]

Oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) should also be distinguished from intravenous NAD. The route changes the intervention; capsule studies cannot establish an infusion's benefits or risks.

What the evidence shows

• Shown: NR can raise measured NAD in blood cells. NMN improved muscle insulin sensitivity in one small, selected group of women, and NR produced a preliminary walking signal in peripheral artery disease. [1] [2] [4]

• Not established: prevention of dementia or diabetes, or consistent functional benefit across populations. Null findings for cognition and several metabolic outcomes are part of the evidence. [2] [3] [5] [6]

• What would change the assessment: replicated improvements in patient outcomes in a clearly defined population, with follow-up long enough to assess lasting benefit and uncommon harm. Ingredient eligibility or a higher NAD result cannot substitute for those outcomes.

What an NAD increase measures

Nicotinamide adenine dinucleotide, or NAD, participates in cellular energy reactions and processes that maintain cell function. NR and NMN are precursors: starting materials the body can use in NAD-related pathways. They are distinct compounds, not alternative names for NAD or automatically interchangeable products. [1] [11]

In a 2018 randomized crossover trial, 30 healthy middle-aged and older adults entered a comparison of NR chloride and placebo, and 24 completed both six-week periods. In a crossover study, the same participant receives both interventions at different times. NR increased NAD in circulating immune cells. That demonstrated a biological effect under the trial conditions. Exploratory cardiovascular findings did not establish prevention of heart attacks. [1]

A biomarker measures a step in a longer proposed chain: a supplement must be absorbed or metabolized, affect the relevant tissue and ultimately improve something that matters to a person. A change in the first steps does not establish the last.

Even “NAD level” needs a sample type. Whole blood, a specific group of blood cells and muscle are different measurements. An increase in one cannot be assumed to occur throughout the body. A higher number also does not by itself show that someone was deficient, that the new value is optimal or that repeated supplementation will produce lasting benefit. [1] [4]

Five trials with different answers

Insulin sensitivity describes how well tissues respond to insulin. Prediabetes means glucose levels are elevated without reaching the diabetes range. The favorable NMN muscle finding and the null NR result in men do not cancel each other out: the compounds and participants differed. Together, they argue for testing specific uses rather than presenting the entire category as an established metabolic treatment. [2] [3]

The walking result was positive by an exploratory rule

Peripheral artery disease limits blood flow to the limbs. In NICE, the NR group's change in six-minute walking distance at six months was 17.6 meters better than placebo. The trial had specified a one-sided significance threshold of 0.10; the comparison's P value was 0.08, so it met that exploratory criterion. [4]

A one-sided test focuses on a difference in a specified direction; a two-sided test considers differences in either direction. This trial's design accepts more uncertainty than the conventional two-sided 0.05 threshold used in many confirmatory trials. It is a preliminary positive finding that needs confirmation. Adding resveratrol did not improve the result. The finding applies to people with peripheral artery disease, not healthy adults seeking more energy. [4]

A publisher correction restored an omitted trial registration number; it did not change the reported results. [4]

The memory and exercise trials sharpen the distinction

Amnestic mild cognitive impairment involves memory difficulties. In the 2026 pilot, 42 people completed the trial: 22 assigned to NR and 20 to placebo. Blood NAD approximately doubled in the NR group, but cognition, total blood flow to the brain and blood pressure did not improve over 12 weeks. Exploratory findings in individual brain regions may guide future studies; they do not overturn the null primary cognitive outcome or demonstrate dementia prevention. [5]

The Friedreich's ataxia trial studied a different problem. This inherited neurological disease affects function and exercise capacity. The 66 participants included children and adults aged 10–40; half were children. After 12 weeks, NR plus individualized exercise improved peak exercise capacity, measured by peak oxygen uptake during an exercise test, compared with placebo and no exercise. [14]

The crucial comparisons are with the individual components. NR alone did not show a significant advantage over control, and the combination was not significantly better than exercise alone. It would therefore be inaccurate to assign the entire combined effect to NR or conclude that the supplement added a demonstrated benefit to exercise. This disease-specific study is not evidence of healthier aging in the general population. [14]

What the broader metabolic review found

A 2026 systematic review of oral NMN and related preparations included 15 trials lasting 14 days to 24 weeks. The pooled results did not show convincing improvements in weight, fasting glucose, HbA1c—a measure of longer-term glucose control—or blood lipid measures. A small reduction in diastolic blood pressure, the lower reading, did not establish a broad metabolic benefit. [6]

The review combined different preparations and study settings. A pooled average is useful context, but it does not make those products or populations identical. These short studies also cannot determine whether a possible effect lasts for years.

Short-term tolerance and product quality answer different questions

Several short studies found no major treatment-related safety signal. That is useful within the exposure studied. Trials with dozens of participants followed for weeks are less able to reveal rare harms or consequences of use over years. They do not prove that the supplements are harmful; they leave long-term benefit and risk uncertain. [1] [3] [5] [6]

For a healthy person, an uncertain benefit has to be considered alongside possible medicine interactions, unwanted effects and ongoing cost. A study of one well-defined preparation does not validate every blend sold under the same ingredient name. Other ingredients can make it harder to identify the cause of either a benefit or a symptom. Identity and purity are product-quality questions; neither demonstrates disease prevention.

Review the actual product label and the full medicine and supplement list with a clinician or pharmacist before use. This is especially relevant during treatment for a medical condition, pregnancy or breastfeeding, or preparation for surgery. FDA guidance emphasizes that supplements can interact with medicines and should not replace prescribed treatment. [8]

What the US NMN decision changed

In its September 2025 response to a citizen petition, the US Food and Drug Administration (FDA) reversed its earlier position that NMN was excluded from the dietary supplement definition under a rule concerning ingredients investigated as drugs. Earlier food or supplement marketing was central to the decision. The FDA concluded that this particular exclusion did not apply to NMN. [7]

The response did not approve NMN for longevity or approve every NMN product. Other requirements remained, including applicable obligations for new dietary ingredients. Identity, manufacturing, labeling and safety requirements still matter. FDA does not approve dietary supplements for safety and effectiveness before they are sold. [7] [8]

NR has a separate US regulatory history. The FDA's August 3, 2016 response to GRAS Notice No. 635 concerned nicotinamide riboside chloride in specified conventional-food uses. GRAS means “generally recognized as safe” for the intended use. The agency's “no questions” response to the notifier's safety conclusion was not approval of an anti-aging treatment and did not substantiate anti-aging health claims. [9]

For any regulatory claim, the useful details are the chemical form, product category, intended use, jurisdiction and actual decision. A logo or the phrase “FDA recognized” does not supply those details.

What the European documents establish

US decisions do not determine status in the European Union, including Czechia. Nicotinamide riboside chloride received an EU novel-food authorization in 2020, with uses and specifications amended in 2022. The authorization applies to specified uses and conditions. Its entry appears in the Union list consolidated through August 10, 2026. Food authorization answers a regulatory question; treatment claims need clinical evidence. [10] [13]

NMN has a different history. An October 11, 2022 consultation through the Czech competent authority classified the assessed NMN ingredient as a novel food. That is a classification, not a market authorization. [12]

The European Food Safety Authority (EFSA) published a favorable safety opinion on May 11, 2026, amended July 8, for a particular chemically synthesized beta-NMN preparation under proposed adult supplement conditions, excluding pregnancy and breastfeeding. It evaluated safety and nutrient availability, not the effectiveness of claimed health benefits. [11]

An EFSA scientific opinion and a European Commission authorization are separate steps. The August 10, 2026 consolidated Union list included NR chloride but no NMN entry. That dated list does not provide blanket permission for NMN products or settle the status of any later authorization. A current product-specific check is needed. A product's EU or Czech market eligibility depends on the applicable authorization and its conditions; a US decision or favorable EFSA opinion alone cannot establish it. [11] [12] [13]

How Healthy Longevity Clinic experts evaluate the evidence

For someone seeking better memory, energy or metabolic health, the useful starting point is the intended outcome. The memory trial makes the main distinction tangible: doubling blood NAD did not improve cognition. The favorable muscle-insulin and walking findings are worth studying further, but their selected populations do not justify a general promise to otherwise healthy adults. [2] [4] [5]

A clinical conversation should therefore ask whether a controlled trial of the exact ingredient tested the goal the person cares about, whether similar people participated and whether the main result improved. The Friedreich's ataxia study adds a second useful test: a successful combination does not prove that the supplement contributed additional benefit. [14]

For unexplained fatigue or memory concerns, an NAD increase does not identify the cause of the symptom. Assessment of the underlying problem remains separate from deciding whether to buy a supplement. Product purity and permission to market an ingredient are relevant, but neither settles whether the person will feel or function better.

Repeated, adequately controlled benefits for cognition, walking or a metabolic condition, alongside longer safety follow-up, would change the assessment. Until then, the evidence supports targeted research into NR and NMN rather than treating them as established longevity medicines. A useful decision weighs patient outcomes, safety, cost and the person's actual care options.

Three questions for a clinician or pharmacist

1. Which outcome am I trying to improve, and did a controlled trial of this ingredient improve it in people similar to me?

2. What do my medicines, health conditions and the exact product formulation change about the possible risks and alternatives?

3. How would we judge a meaningful benefit or a reason to stop, and what does the relevant regulatory document actually permit?

Common questions

Does a higher blood NAD result mean slower aging?

No. It demonstrates a change in that measurement. It does not establish a body-wide deficiency has been corrected or that memory or daily function will improve. The 2026 memory trial raised NAD without improving its main cognitive outcome. [1] [5]

Did the walking trial show a benefit or not?

It met its prespecified exploratory statistical criterion: a 17.6-meter advantage with P = 0.08 under a one-sided 0.10 threshold. The finding merits confirmation in people with peripheral artery disease; it is not a proven energy benefit for healthy adults. [4]

Does the FDA's NMN decision mean it approved an anti-aging supplement?

No. The September 2025 response removed one statutory exclusion from the supplement definition. Other obligations remained, and the decision did not establish longevity efficacy or approve every product. [7] [8]

Can evidence for capsules support an NAD infusion?

No. Oral precursors and intravenous NAD are different interventions. Evidence must match the route, preparation and outcome being claimed.